Theodore A. Bass, MD

Sirolimus-Eluting Stents for Treatment of Complex Bypass Graft Disease: Insights from the SECURE Registry

08/01/2008

Marco A. Costa , MD, PhD;

Andrew J. Carter , DO, FACC;

Paul S. Teirstein , MD, FACC;

Martin B. Leon , MD;

Martin Zenni , MD;

Theodore A. Bass , MD;

Steven J. Yakubov , MD;

Paul Gilmore , MD;

Jeffrey W. Moses , MD;

Tim A. Fischell , MD, FACC, FSCAI;

Dominick J. Angiolillo , MD, PhD;

Treatment options for bypass graft disease, such as repeat CABG and percutaneous revascularization, are limited and provide disappointing outcomes.1-4 Patients undergoing repeat CABG have over a four times greater rate of mortality compared...

Treatment options for bypass...

08/01/2008

Journal of Invasive Cardiology

Sirolimus-Eluting Stent for Complex Lesions:Treatment of Saphenous Vein Graft Disease

06/19/2008

Theodore A. Bass , MD;

Marco A. Costa , MD, PhD;

It is estimated that 40% of saphenous vein grafts (SVG) are occluded and a higher number develop significant stenosis within 10 years after operation.1 Our treatment options have been limited and disappointing. When treated with conventional...

It is estimated that 40% of...

06/19/2008

Cath Lab Digest

Feature

Sirolimus-Eluting Stent for Complex Lesions:Treatment of Saphenous Vein Graft Disease

06/19/2008

Marco A. Costa , MD, PhD;

Theodore A. Bass , MD;

It is estimated that 40% of...

06/19/2008

Cath Lab Digest